Yesterday Johnson and Johnson and its global partners announced that they would discontinue the large-scale Imbokodo HIV Vaccine Trial. Initial results showed that the vaccine did not provide significant protection against HIV infection in young women in sub-Saharan Africa. Despite this disappointing news, IAS – the International AIDS Society – emphasizes the importance of continued investment […]
An event to engage scientists, clinicians, industry, funders, and community representatives on how best to learn from past efficacy trials to inform future vaccine development efforts.
Today, the Journal of the International AIDS Society (JIAS) commemorates HIV Vaccine Awareness Day and reflects on the long-standing efforts to develop an HIV vaccine and the significance of SARS-CoV-2 vaccine development over the past year for the future of HIV vaccine research.
The Global HIV Vaccine Enterprise at the IAS – International AIDS Society, and IAVI, are pleased to announce a Communication Training Workshop for early-mid career African researchers working in HIV vaccine research and development.
The Global HIV Vaccine Enterprise at the IAS – International AIDS Society, and IAVI, are pleased to announce a Communication Training Workshop for early-mid career African researchers working in HIV vaccine research and development.
The Global HIV Vaccine Enterprise at the IAS – International AIDS Society, and IAVI, are pleased to announce a Communication Training Workshop for early-mid career African researchers working in HIV vaccine research and development.
In this presentation, Dr. Roger Tatoud, presents the finding of an investigation led by the Enterprise to identify and characterize the ways in which HIV vaccine R&D has contributed to the early success of the COVID-19 vaccine response, the extent to which it has contributed across various dimensions, and the uniqueness of its contributions relative to other fields.
The IAS-led Global HIV Vaccine Enterprise welcomes new results from the AMP proof-of-concept studies (HVTN 704/HPTN 085 and HVTN 703/HPTN 081) demonstrating that infusions of the broadly neutralizing monoclonal HIV antibody (bNAb) VRC01 can prevent some HIV infections.
HIV vaccine highlights and spotlights – To help attendees manage their time and navigate a busy programme, the Enterprise has developed an HIV vaccine R&D roadmap which covers active immunization and passive immunization with broadly neutralizing antibodies (bNAbs), especially VRC01.
